Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Shire Plc. : Shire Buying Pervasis To Advance Regenerative Medicines Business

share with twitter share with LinkedIn share with facebook
share via e-mail
04/12/2012 | 05:49pm CET
  By Sten Stovall 

Shire PLC (SHP.LN) is buying the assets of U.S.-based Pervasis Therapeutics in a deal that brings a new technology aimed at improving blood vessel repair for dialysis patients to the U.K. drug maker's regenerative medicine business.

A specialist in hyperactivity and rare genetic diseases, Shire is also expanding its activities in regenerative medicine to find products for replacing human cells, tissues or organs to restore or establish normal function.

Toward that end, Shire on Thursday said it will pay Pervasis an undisclosed upfront payment, plus milestones if Pervasis' lead product, a cell-based therapy called Vascugel, hits certain clinical, regulatory and sales targets. No financial terms were disclosed.

Pervasis, based in Cambridge, Massachusetts, is developing acute vascular repair technologies for patients with end-stage renal disease, or ESRD, which is an advanced and irreversible kidney disease. There are around 600,000 people in the U.S. and more than 250,000 in the EU currently being treated for ESRD.

Shire said its deal with Pervasis will make a strong strategic fit with its existing Dermagraft treatment for diabetic foot ulcers.

Diabetes is the chief cause of ESRD, while diabetic patients on dialysis have a greater risk of developing a diabetic foot ulcer than diabetics not receiving dialysis treatment.

Shire's head of regenerative medicine, Kevin Rakin, said that "this acquisition marks a very important step for Shire in building a regenerative medicine business focused on tissue repair and regeneration."

He told Dow Jones Newswires that Vascugel is currently in mid-stage clinical trials and will be progressing to late-stage Phase III testing soon. Vascugel has received Orphan Product designation from the U.S. Food and Drug Administration and from the European Medical Agency. If all goes well, marketing authorization could be sought for Vascugel by 2017, Rakin said.

Pervasis will give Shire a new cell-based technology platform called endothelial cell technology that has global potential. "We are looking at generating other products out of this platform," Rakin said.

"We're building our regenerative medicine activities because we believe it's one of the next big areas of medicine and so this adds to the Dermagraft purchase and we're building up our pipeline now. We're committed to doing this."

- By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE
12/15 SHIRE : New Formulation of ONCASPAR Receives Marketing Authorization in Europe f..
12/14 SHIRE : Novel Clinical Study Collaboration Announced Designed to Improve Clinica..
12/13 SHIRE : New Formulation of ONCASPAR®▼ (pegaspargase) Receives Marketing Au..
12/13 SHIRE PLC : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Autho..
12/11 SHIRE : Chief Financial Officer update
12/08DJSHIRE : Names John Miller as Interim CFO From Jan. 1
12/08 SHIRE : Chief Financial Officer update
12/08DJSHIRE PLC SHIRE PLC : Directorate Change
12/08 SHIRE PLC : Directorate change
12/08 SHIRE : `Orphan drugs` specialist Shire to expand India presence
More news
News from SeekingAlpha
12/15 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 15, 2017
12/13 EC OKs new formulation of Shire's Oncaspar with longer shelf life
12/07 COBAS ASSET MANAGEMENT : Comments On Third Quarter 2017
12/07 YOUR DAILY PHARMA SCOOP : Gilead's Potential, Celgene CAR-T Candidate, Cellectar..
12/06 NASH drug developers in the red after Madrigal's mid-stage success with MGL-3..
Financials ($)
Sales 2017 14 936 M
EBIT 2017 5 736 M
Net income 2017 2 313 M
Debt 2017 19 275 M
Yield 2017 0,71%
P/E ratio 2017 19,77
P/E ratio 2018 13,06
EV / Sales 2017 4,34x
EV / Sales 2018 3,94x
Capitalization 45 581 M
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Technical analysis trends SHIRE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 67,8 $
Spread / Average Target 35%
EPS Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Howard Mayer Senior VP & Head-Research & Development
Matt Walker Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE-19.67%45 962
JOHNSON & JOHNSON23.65%382 722
PFIZER14.53%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.4.94%212 270
MERCK AND COMPANY-4.47%153 386